Radiation Oncology/Breast/LCIS

From Wikibooks, the open-content textbooks collection

Front Page: Radiation Oncology | RTOG Trials

Breast: Main Page | Staging | Breast Overview | Prevention | Benign | DCIS | LCIS | Paget's | Phyllodes tumor | Early stage | Advanced stage | Post mastectomy | Inflammatory | Partial breast irradiation | Regional lymphatics | Hormonal therapy | Chemotherapy | RT technique | Recurrence | Toxicity of RT | Randomized | NSABP trials

[edit] Risk of invasive cancer

• SEER data, 2005 (1973-98) - PMID 16110014 — "Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data." Chuba PJ et al. J Clin Oncol. 2005 Aug 20;23(24):5534-41.
  • Incidence of invasive carcinoma 7.1% at 10 yrs, 18% at 25 yrs.
  • 46% ipsilateral / 54% contralateral. Higher proportion of cancers with ILC than in the general population (23.1% vs 6.5%).
  • Conclusion: LCIS is associated with increased risk of subsequent invasive breast cancer, which can occur with roughly equal probability in either breast.

[edit] Prevention of invasive cancer

• P-1 prevention trial
  • See page at Prevention for detail.
  • 43% risk reduction with tamoxifen overall (46% for those with LCIS).

[edit] Surgery alone

• NSABP - PMID 14716756 — "Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ." Fisher ER et al. Cancer. 2004 Jan 15;100(2):238-44.
  • Analysis of previous NSABP trial. 12-year results of 180 pts treated with surgical excision only.
  • IBTR in 14.4% and CBTR in 7.8%. 9 of 26 IBTR and 10 of 14 CBTR were invasive, mostly invasive lobular carcinoma.
  • Conclusion: LCIS is an indolent disease and can be managed with conservative surgery